The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer – and the challenges they face due to stigma and health inequities – come together in the form of a new, intentionally difficult-to-read book from Gilead.
Responsible Business & Employee Engagement
| Gilead Sciences
When employees at Gilead’s recently opened New Jersey office need a place to meet, the “Cara” conference room is one such place they gather. Given the room’s namesake, it’s especially fitting when the topic at hand is the company’s oncology work.
Philanthropy & Cause Initiatives
| Gilead Sciences
Nearly 36 years ago the AIDS Memorial Quilt was displayed for the first time to memorialize and physically represent lives lost to HIV. Gilead has always actively supported the Quilt, and creating a new panel made sense for a company dedicated to helping end the HIV epidemic.
Dr. Shringar Rao’s inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs.
Listen to episode 2 of our Hepcast as we follow the journey of a young man living with HepatitisB. He’s joined by Arafat Bwambale from the Great Lakes Peace Centre in Uganda and Manal El Sayed from Ain Shams University in Egypt.
The Social Justice Experience is a virtual, interactive platform that examines the Black American experience with a timeline of Black history in America dating back to 1619.
Dr. Sara Tolaney oversees an independent and diverse scientific review committee composed of experts in oncology who review all applications and select who will receive funding. Diversity is at the forefront of her mind.
Congratulations to Michael Elliott, Vice President of Development and Medical Affairs at Gilead, for being named to this year's Empower Advocate Executive Role Model List.
We’re pleased to announce that we're joining the global Access to Oncology Medicines (ATOM) Coalition to help improve care and access to essential cancer medicines in low- and lower middle-income countries.
“Gilead's support for community organizations is part of our enduring commitment to ending the HIV epidemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.
Gilead scientists had planned for a moment like this through years of research. When coronaviruses with pandemic potential, like SARS and MERS, emerged in the early 2000s, Gilead began searching for potential new antivirals.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...